Advertisement
U.S. markets open in 5 hours 28 minutes
  • S&P Futures

    5,304.50
    -3.75 (-0.07%)
     
  • Dow Futures

    40,106.00
    -38.00 (-0.09%)
     
  • Nasdaq Futures

    18,502.75
    -1.00 (-0.01%)
     
  • Russell 2000 Futures

    2,135.00
    -3.40 (-0.16%)
     
  • Crude Oil

    81.71
    +0.36 (+0.44%)
     
  • Gold

    2,213.30
    +0.60 (+0.03%)
     
  • Silver

    24.61
    -0.14 (-0.57%)
     
  • EUR/USD

    1.0800
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.95
    +0.17 (+1.33%)
     
  • GBP/USD

    1.2612
    -0.0026 (-0.21%)
     
  • USD/JPY

    151.4270
    +0.1810 (+0.12%)
     
  • Bitcoin USD

    70,384.00
    +594.25 (+0.85%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,931.98
    0.00 (0.00%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

Krystal Biotech, Inc.
Krystal Biotech, Inc.

PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Chardan’s 6th Annual Genetic Medicines Conference in New York from October 3-4.

Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on October 4.

A webcast of the presentation will be available here beginning at 9:00am ET on Tuesday, October 4 and will be posted on the Investor section of the Company’s website.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.

CONTACT:

Investors and Media
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Source: Krystal Biotech, Inc.


Advertisement